Monchana Nawakitrangsan
Overview
Explore the profile of Monchana Nawakitrangsan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boonpeng A, Jaruratanasirikul S, Wattanavijitkul T, Nawakitrangsan M, Samaeng M
Biopharm Drug Dispos
. 2021 Jun;
42(7):329-337.
PMID: 34117648
Levofloxacin is considered a key component of a multidrug-resistant tuberculosis (MDR-TB) regimen. However, there is considerable concern regarding the subtherapeutic concentrations of the currently used doses and the development of...
2.
Jaruratanasirikul S, Boonpeng A, Nawakitrangsan M, Samaeng M
Pharmacotherapy
. 2021 Jun;
41(7):572-597.
PMID: 34080708
Study Objectives: The objectives of this study were (i) to determine the population pharmacokinetic (PK) of imipenem in critically ill patients with life-threatening severe infections, (ii) to investigate the impact...
3.
Jaruratanasirikul S, Vattanavanit V, Wongpoowarak W, Nawakitrangsan M, Samaeng M
Eur J Drug Metab Pharmacokinet
. 2020 Sep;
45(6):735-747.
PMID: 32886347
Background: Extracorporeal membrane oxygenation (ECMO), a cardiopulmonary bypass device, has been found to increase the profound pathophysiological changes associated with life-threatening severe infections in patients with multiple comorbidities, which results...
4.
Jaruratanasirikul S, Nitchot W, Wongpoowarak W, Samaeng M, Nawakitrangsan M
Eur J Pharm Sci
. 2019 May;
136:104940.
PMID: 31132402
Background: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Acinetobacter baumannii remains one of the leading causes of the high mortality rate in critically ill patients. Sulbactam has been considered as...
5.
Jaruratanasirikul S, Vattanavanit V, Samaeng M, Nawakitrangsan M, Sriwiriyajan S
Clin Drug Investig
. 2019 May;
39(8):787-798.
PMID: 31124013
Background: Extracorporeal membrane oxygenation (ECMO) has become increasingly used for lifesaving respiratory and/or cardiac failure support in critically ill patients, including those with life-threatening severe infections. This cardiopulmonary bypass device...
6.
Jaruratanasirikul S, Jaspattananon A, Wongpoowarak W, Nawakitrangsan M, Thengyai S, Samaeng M
J Med Assoc Thai
. 2018 Jun;
99(8):886-92.
PMID: 29947489
Background: Levofloxacin, a fluoroquinolone, is an isomer of ofloxacin with an extensive spectrum of antimicrobial efficacy. In common with other fluoroquinolones, the main pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with its...
7.
Jaruratanasirikul S, Wongpoowarak W, Wattanavijitkul T, Sukarnjanaset W, Samaeng M, Nawakitrangsan M, et al.
Antimicrob Agents Chemother
. 2016 Sep;
60(12):7236-7244.
PMID: 27671056
Sulbactam is being considered as an alternative concomitant medication with other effective antibiotics for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections. Pathophysiological changes in critically ill patients with severe...